Impact of Prior Antiplatelet Therapy on Risk of Embolism in Infective Endocarditis | Zendy

Namrata S Anavekar | Zendy; Imad M. Tleyjeh | Zendy; Zaur Mirzoyev | Zendy; James M. Steckelberg | Zendy; Christelle Haddad | Zendy; Masud H. Khandaker | Zendy; Walter R. Wilson | Zendy; Krishnaswamy Chandrasekaran | Zendy; Larry M. Baddour | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of Prior Antiplatelet Therapy on Risk of Embolism in Infective Endocarditis

Author(s) -

Namrata S Anavekar,

Imad M. Tleyjeh,

Zaur Mirzoyev,

James M. Steckelberg,

Christelle Haddad,

Masud H. Khandaker,

Walter R. Wilson,

Krishnaswamy Chandrasekaran,

Larry M. Baddour

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/513197

Subject(s) - medicine , infective endocarditis , endocarditis , embolism , bacteremia , intensive care medicine , surgery , antibiotics , microbiology and biotechnology , biology

Embolism is a dreaded complication of infective endocarditis (IE). Currently, antimicrobial therapy is the only medical intervention proven to decrease the risk of embolism associated with IE. We hypothesized that, because platelet aggregation is operative in the pathogenesis of vegetation formation, embolism associated with IE should occur less frequently among patients who have received prior, continuous daily antiplatelet therapy for noninfectious reasons.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research